Vanadium and Diabetes
Research studies have demonstrated that several genes of insulin signaling pathway are involved in the effect of Vanadium treatment of hyperglycemia. (Ref 1)
It has been found that the poly oxovanadium complex exhibits potent antidiabetic activity in diabetes type I and type 2 in mice. (Ref 2)
Studies indicate that the oral vanadyl acetyl acetonate is well tolerated and benefits diabetic osteopathy of rats and improves diabetes related bone disorders particularly by improving the diabetic state. (Ref 3)
Vanadium is a well known anti-diabetic agent which mimics most of the actions of insulin on mature adipocytes. Studies (Ref 4) show a new dimension in vanadium treatment for diabetes due to its novel role in adipogenensis.
Bis oxovanadium (IV) is a new orally active anti-diabetic organic vanadium complex and it has anti-diabetic and insulin-sensitizing effects in diabetic rats, exhibiting the potential to be developed as a new therapeutic agent for type 2 diabetes. (Ref 5)
Bis oxovanadium (IV) is a safe and potent agent for diabetes treatment because it is able to improve carbohydrate metabolism and to reduce oxidative stress. (Ref 6)
Vanadyl sulfate and taurine are two promising agents in the treatment of diabetes related to their antihyperglycemic, antihyperlipemic, and hyperinsulinemic effects. (Ref 7)
An oxovanadium complex has been tested for bioactivity as an insulin enhancing agent and results showed that the complex at specific doses could lower the blood glucose level in 
Oxovanadium is proposed to be an orally active complex for treating type I diabetes and type 2 diabetes in animals. (Ref 9)
A review has been done regarding vanadium’s glucose-enhancing potential, its biodistribution, and biomolecular transformation and its mechanism of action in diabetes treatment. (Ref 10)
The diabetes-associated biochemical and morphological alterations in Golgi complexes were investigated and results showed that sodium metavandate affected diabetic rat liver Golgi complexes. (Ref 11)
Insulin-mimetic vanadyl-poly complex is proposed as a novel drug delivery system for treating type 1 diabetic animals and results showed improvement in diabetes as seen by results on oral glucose tolerance test, HbA(1c) levels, and blood pressure. (Ref 13, 14)
Research data indicate immense hypoglycemic activity and reduced toxicity of oxovanadium complex. (Ref 15)
Treatment with Vanadium, a representative of class of anti-diabetic compounds alleviates hyperglycemia and hyperlipidemia. Oral administration of vanadium compounds in animal models and humans does not cause clinical symptoms of hypoglycemia, a common problem for diabetic patients with insulin treatment. (Ref 16)
Studies have showed that vanadyl sulfate trihydrate can inhibit c AMP dependent protein kinase. (Ref 17)
Among several metals, Vanadium has emerged as an extremely potent agent with insulin-like properties. These insulin-like properties have been demonstrated in isolated cells, tissues, different animal models of type 1 an dtype2 diabetes as well as on a limited number of human subjects. Insulin signal mimicry is suggested as a mechanism for the insulin-like effects of Vanadium.
- Effect of vanadate on gene expression of the insulin signaling pathway in skeletal muscle of streptozotocin-induced diabetic rats.
- Amelioration of Hyperglycemia and Metabolic Syndromes in Type 2 Diabetic KKA(y) Mice by Poly (gamma-glutamic acid) oxovanadium (IV) Complex.
- Effects on the bones of vanadyl acetylacetonate by oral administration: a comparison study in diabetic rats. J Bone Miner Metab. 2007; 25(5):293-301. Epub 2007 Aug 25.
- Adipogenic action of vanadium: a new dimension in treating diabetes.
- Effects of bis(alpha-furancarboxylato)oxovanadium(IV) on glucose metabolism in fat-fed/streptozotocin-diabetic rats. Eur J Pharmacol. 2007 Oct 31; 572(2-3):213-9. Epub 2007 Jun 19.
- Bis (quercetinato) oxovanadium IV Reverses Metabolic Changes in Streptozotocin-Induced Diabetic Mice.
- Vanadyl sulfate, taurine, and combined vanadyl sulfate and taurine treatments in diabetic rats: effects on the oxidative and antioxidative systems.
- In vivo insulin-mimetic activity of [N, N’-1, 3-propyl-bis (salicyladimine)]oxovanadium(IV).
- Improvement of hyperglycaemia and metabolic syndromes in type 2 diabetic KKAy mice by oral treatment with [meso-tetrakis (4-sulfonatophenyl) porphyrinato] oxovanadium (IV) (4- ) complex.
- Vanadium in diabetes: 100 years from Phase 0 to Phase I.
- Sodium metavanadate affected control and streptozotocin-diabetic rat liver golgi complexes. Pol J Pathol. 2006; 57(2):91-7.
- Follow-up studies on glycosylated flavonoids and their complexes with vanadium: their anti-hyperglycemic potential role in diabetes.
- A novel drug delivery system for type 1 diabetes: insulin-mimetic vanadyl-poly (gamma-glutamic acid) complex.
- Bis (allixinato) oxovanadium (IV) complex is a potent antidiabetic agent: studies on structure-activity relationship for a series of hydroxypyrone-vanadium complexes.
- Reduction of oxidative stress induced vanadium toxicity by complexing with a flavonoid, quercetin: a pragmatic therapeutic approach for diabetes.
- Diabetes-altered gene expression in rat skeletal muscle corrected by oral administration of vanadyl sulfate.
No Comments